RNAseq analysis for lung resident cells from protease allergen and FK506 treated mice

There is evidence for the beneficial effect of FK506, an effective immunosuppressive agent, for the treatment of asthma; however, the mechanisms underlying these effects are unclear. Using a mouse model of airway inflammation induced by Papain, a protease allergen, and RNAseq analysis of lung innate cells, we found that FK506 inhibited the activation of ILC2s, which initiate airway inflammation, as well as the induction of TH2 cells, which cause chronic inflammation. Our findings further support the clinical value of FK506 for the treatment of allergen-induced airway inflammation and clarify its targets and mechanisms of action. Overall design: Lung ILC2 cells, epithlial cells (type 1: AEC1 and type 2: AEC2), and basophils of mice were sorted and analyzed the transcriptome using Illumina HiSeq1500.